Summary & Overview
HCPCS G8871: Patient Not Receiving First Course of Anti-TNF Therapy
HCPCS Level II code G8871 documents that a patient is not receiving a first course of anti‑TNF (anti‑tumor necrosis factor) therapy. This code is used in outpatient specialty and ambulatory settings—commonly rheumatology and gastroenterology clinics—to record treatment status and support clinical reporting. Nationally, consistent use of a designated HCPCS code for anti‑TNF treatment status helps standardize reporting across payers, inform utilization tracking, and support quality measurement related to biologic therapy initiation.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical meaning and service context, plus what to expect in payer coverage patterns and reporting: benchmarks for use frequency, relevant policy and coding updates, and the clinical context for when G8871 is applied. The publication outlines common scenarios for documentation, implications for encounter-level reporting, and links to related billing considerations. Data limitations are noted when source details are not provided.
Billing Code Overview
HCPCS Level II code G8871 indicates a patient not receiving a first course of anti-TNF therapy. This code documents the clinical status that the patient has not been started on anti-tumor necrosis factor therapy as an initial biologic treatment.
-
Service type: Documentation of biologic therapy status / treatment decision support
-
Typical site of service: Outpatient specialty clinics (rheumatology, gastroenterology) and ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with an immune-mediated inflammatory disease (for example, moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease) is evaluated for biologic therapy. The clinician documents that the patient is not currently receiving a first course of anti-TNF (tumor necrosis factor) therapy and plans initiation of a biologic other than an anti-TNF agent or deferral of anti-TNF therapy. Typical workflow: outpatient specialty visit (rheumatology, gastroenterology, or dermatology) with history, medication review, disease activity assessment, and documentation of prior therapies; review of prior authorization requirements; laboratory screening (hepatitis B, hepatitis C, TB testing, CBC, CMP) and vaccination status determination; shared decision-making discussion recorded in the chart noting that patient is not receiving a first course of anti-TNF therapy. This billing descriptor G8871 is used to indicate the patient is not receiving a first course of anti-TNF therapy when reporting quality or care-status measures during the visit. Typical site of service: outpatient specialty clinic or ambulatory care center. Typical patient scenario: a 52-year-old patient with active moderate rheumatoid arthritis previously treated with methotrexate and corticosteroids, evaluated for escalation to a biologic; clinician documents that anti-TNF therapy is not being started as the first biologic option and records the reason and plan in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |